Osimertinib Extended OS in EGFR-Mutated Advanced NSCLC
The third-generation drug performed better than erlotinib or gefitinib, according to researchers.
Diagnosis & Disease Information
One-Third of Glioblastomas Had Molecular Changes at Recurrence
Repeat biopsies may be needed prior to patient inclusion in targeted-therapy trials.
Testing for Genetic Variants Informed the Use of Cancer Risk Assessments
Genetic testing provided important information beyond personal and family history.
Insurance Plans Dropping Coverage of FDA-approved BRCA Diagnostic Test
Some health care insurers have stopped covering this FDA-approved genetic test, instead limiting coverage only for cheaper, lower-quality genetic tests.
Patterns in PI3K Signaling Pathway Aberrations Evaluated
Researchers argue that combination therapies targeting both mutations in the PI3K pathway and HER2 or hormone receptor overexpression should be evaluated across cancer types.
Precision Medicine Associated With Improved Outcomes in Early Trials
Patients whose treatment was based on the molecular characteristics of their particular tumor had significantly better outcomes compared with patients who did not.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...